Table 5.
Patient-level outcomes: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 9.0% [75 mol/mol], target HbA1c of 7.0% [53 mmol/mol])
| Intensification delay, years | Time horizon, years | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 5 | 10 | 30 | |
| Reduction in life expectancy with poor glycemic control, years | ||||||
| 1 | 0.001 | 0.002 | 0.004 | 0.01 | 0.02 | 0.05 |
| 2 | – | 0.002 | 0.004 | 0.01 | 0.03 | 0.09 |
| 3 | – | – | 0.01 | 0.01 | 0.03 | 0.13 |
| 5 | – | – | – | 0.01 | 0.04 | 0.18 |
| 7 | – | – | – | – | 0.05 | 0.22 |
| Cost of diabetes related complications, USD | ||||||
| 1 | 131 | 225 | 287 | 387 | 725 | 1243 |
| 2 | – | 306 | 434 | 635 | 1212 | 2335 |
| 3 | – | – | 507 | 862 | 1624 | 3186 |
| 5 | – | – | – | 1067 | 2320 | 4885 |
| 7 | – | – | – | – | 2782 | 6172 |
| Lost productivity costs, USD | ||||||
| 1 | 415 | 679 | 881 | 1232 | 2329 | 2581 |
| 2 | – | 974 | 1369 | 2035 | 4024 | 4581 |
| 3 | – | – | 1674 | 2740 | 5132 | 6243 |
| 5 | – | – | – | 3427 | 7264 | 8531 |
| 7 | – | – | – | – | 8641 | 10,507 |
| Total costs, USD | ||||||
| 1 | 546 | 904 | 1168 | 1619 | 3054 | 3823 |
| 2 | – | 1280 | 1803 | 2670 | 5236 | 6916 |
| 3 | – | – | 2181 | 3601 | 6756 | 9429 |
| 5 | – | – | – | 4494 | 9583 | 13,416 |
| 7 | – | – | – | – | 11,423 | 16,679 |
HbA1c glycated hemoglobin, USD United States dollars